Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Experimental: Cohort A: PD-L1 TPS≥ 1%

Adagrasib 400mg twice daily (BID) x 2 cycles followed by adagrasib 400mg BID in combination with pembrolizumab

Drug: Adagrasib in combination with pembrolizumab

Adagrasib will be administered orally twice daily in a continuous regimen

Biological: Pembrolizumab

Pembrolizumab will be administered as an intravenous infusion once every 3 weeks

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 14, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments